DAL BEN, Diego
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.391
EU - Europa 6.955
AS - Asia 4.661
SA - Sud America 600
Continente sconosciuto - Info sul continente non disponibili 462
AF - Africa 203
OC - Oceania 12
Totale 27.284
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.946
CN - Cina 1.871
PL - Polonia 1.721
SG - Singapore 1.374
RU - Federazione Russa 1.327
IT - Italia 1.284
DE - Germania 597
BR - Brasile 494
GB - Regno Unito 469
HK - Hong Kong 393
FR - Francia 370
VN - Vietnam 361
UA - Ucraina 338
CA - Canada 336
SE - Svezia 261
FI - Finlandia 221
KR - Corea 153
ZA - Sudafrica 139
TR - Turchia 132
IE - Irlanda 93
IN - India 90
JP - Giappone 69
NL - Olanda 64
BD - Bangladesh 44
MX - Messico 44
BE - Belgio 40
AR - Argentina 38
ES - Italia 31
EU - Europa 27
AT - Austria 22
EC - Ecuador 19
IQ - Iraq 19
PK - Pakistan 19
TW - Taiwan 16
CO - Colombia 15
CZ - Repubblica Ceca 15
LT - Lituania 14
AE - Emirati Arabi Uniti 13
KE - Kenya 13
IR - Iran 12
RO - Romania 12
RS - Serbia 12
CH - Svizzera 11
EG - Egitto 11
ID - Indonesia 11
AU - Australia 10
JM - Giamaica 10
PY - Paraguay 10
TN - Tunisia 10
VE - Venezuela 10
HN - Honduras 9
JO - Giordania 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
CR - Costa Rica 8
DK - Danimarca 8
IL - Israele 7
LB - Libano 7
PE - Perù 7
TT - Trinidad e Tobago 7
DZ - Algeria 6
MY - Malesia 6
NI - Nicaragua 6
PH - Filippine 6
AL - Albania 5
AM - Armenia 5
AZ - Azerbaigian 5
HU - Ungheria 5
MA - Marocco 5
BG - Bulgaria 4
CI - Costa d'Avorio 4
DO - Repubblica Dominicana 4
EE - Estonia 4
HR - Croazia 4
NP - Nepal 4
PR - Porto Rico 4
SC - Seychelles 4
SV - El Salvador 4
BB - Barbados 3
BY - Bielorussia 3
CL - Cile 3
ET - Etiopia 3
GR - Grecia 3
GT - Guatemala 3
LV - Lettonia 3
NO - Norvegia 3
PT - Portogallo 3
SI - Slovenia 3
TH - Thailandia 3
BS - Bahamas 2
CW - ???statistics.table.value.countryCode.CW??? 2
GE - Georgia 2
KH - Cambogia 2
KW - Kuwait 2
MM - Myanmar 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
Totale 26.831
Salva come PNG Salva come JPEG
Città #
Warsaw 1.494
Fairfield 1.296
Ashburn 1.285
Woodbridge 972
Jacksonville 794
San Jose 749
Singapore 691
Houston 632
Chandler 567
Seattle 548
Wilmington 517
Council Bluffs 494
Ann Arbor 487
Cambridge 450
Dallas 395
Hong Kong 367
Boardman 356
Beijing 334
Camerino 266
Nanjing 246
Los Angeles 221
Kraków 213
Toronto 207
New York 175
The Dalles 156
Seoul 127
Johannesburg 124
Helsinki 118
San Mateo 117
Tongling 116
Princeton 115
Dearborn 111
Ho Chi Minh City 111
Lawrence 111
Columbus 110
London 107
Istanbul 104
Lauterbourg 100
Chicago 95
Dublin 91
Moscow 91
Santa Clara 91
Ogden 90
Phoenix 87
Düsseldorf 81
Buffalo 75
San Diego 75
Shanghai 75
Nanchang 71
Milan 70
Guangzhou 69
St Louis 68
Hanoi 61
São Paulo 61
Lachine 57
Rome 53
Tokyo 53
Munich 51
Frankfurt am Main 50
Dong Ket 49
Tianjin 49
Kunming 46
Edinburgh 44
Shenyang 43
Orem 42
Brussels 39
Jiaxing 38
Hebei 36
Centro 35
Denver 35
Atlanta 31
San Francisco 31
Changsha 27
Montreal 27
Philadelphia 27
Manchester 26
Hangzhou 25
Trieste 25
Washington 24
Boston 23
Jinan 23
Salt Lake City 23
Wuhan 23
Brooklyn 22
Falls Church 22
Poplar 22
Redwood City 22
Amsterdam 21
Hefei 21
Mexico City 20
Ningbo 20
Norwalk 20
Redondo Beach 20
Scafati 20
Chennai 19
Nuremberg 18
Stockholm 18
Bologna 17
Rio de Janeiro 17
Verona 17
Totale 18.025
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 661
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 468
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 424
Overview on Radiolabel-Free in Vitro Assays for GPCRs 415
Pharmacological characterization of the GPR17 receptor dual profile 413
GPR17 receptor modulators and their therapeutic implications: review of recent patents 410
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 396
The G Protein-Coupled Receptor GPR17: Overview and Update 394
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 390
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 375
Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects 373
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 369
Emerging Roles of Purinergic Signaling in Diabetes 364
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 309
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 307
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 307
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 305
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 297
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 297
P2X7 Receptor as a Therapeutic Target 294
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 288
The P2X7 Receptor in Infection and Inflammation 285
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 277
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 276
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 267
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 265
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 256
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 254
Identification of a specific residue that confers BzATP sensitivity to P2X2 receptors 254
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 249
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 247
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 247
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 245
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 245
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 242
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 241
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 239
Antiviral properties of deazaadenine nucleoside derivatives 237
New sensible method to quantize the intestinal absorption of receptor ligands 234
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 232
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 232
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 231
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 231
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 229
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 226
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 223
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 223
Interaction model for anthracycline activity against DNA topoisomerase II 222
Adenosine receptor modeling: what does the A2A crystal structure tell us? 221
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 221
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 221
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel (18)F-labelled PET tracer targeting P2X7 221
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 219
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 218
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 214
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 213
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 212
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 210
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 209
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 209
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 207
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 205
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 204
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 203
Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives 203
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 202
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 201
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 201
Purinergic P2X receptors: physiological and pathological roles and potential as therapeutic targets 198
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 197
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 197
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 197
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 196
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 193
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 192
Rational design of new competitive inhibitors of human CK2 activity 190
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 187
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 187
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 187
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 186
I protocolli operativi nella violenza di genere 184
DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation 182
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 176
Development of novel pyridazinone-based adenosine receptor ligands 176
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 171
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 166
GTP-Eu binding assay optimization for the adenosine A3 receptor ligands screening 166
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 164
A2A adenosine receptor ligands: effects on alcohol intake in alcohol-preferring rats 163
7th Joint Italian-German Purine Club Meeting - “Advances in basic and translational purinergic research” - 20-22 luglio 2017 162
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 160
Substituted adenine derivatives as novel P2X3 receptor ligands 158
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 158
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 156
New purine derivatives as P2X3 receptor antagonists 156
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 154
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 154
Identification of putative guanosine receptor in rat brain 154
Letters in Drug Design & Discovery 153
Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens 151
Totale 24.250
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.163
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 107.163
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022900 0 0 0 41 67 66 86 124 111 145 92 168
2022/20231.440 164 103 56 230 137 188 9 74 245 70 109 55
2023/20241.247 161 64 80 49 57 114 65 92 138 44 45 338
2024/20254.107 180 74 330 195 135 258 476 1.025 340 283 277 534
2025/20266.206 367 349 702 813 641 453 1.012 451 400 450 357 211
2026/20271.905 558 249 496 602 0 0 0 0 0 0 0 0
Totale 27.284